Light and drug combo takes aim at early Alzheimer's
NCT ID NCT06992804
First seen Sep 30, 2025 · Last updated Apr 30, 2026 · Updated 25 times
Summary
This study tests whether adding near-infrared light therapy to the drug lecanemab can safely improve thinking and memory in people with mild Alzheimer's disease. About 20 participants will receive either real light therapy or a sham device along with lecanemab for 16 weeks, then all will get the real light therapy for up to 48 weeks. The goal is to see if the combination slows cognitive decline better than the drug alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xuanwu Hospital, Capital Medical University
RECRUITINGBeijing, 100053, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.